Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/09
End: 12/31/09
Due: 12/31/10
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Phase: N/A
Priority: Normal
Start: 04/30/20
End: 12/26/20
Due: 12/26/21
Phase: N/A
Priority: Normal
Start: 10/19/21
End: 05/27/22
Due: 05/27/23
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 05/31/12
Due: 05/31/13
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) | NCT00886353 | Apeiron Biologics | user2@example.com | None | 2009-04-30 | 2009-12-31 | 2010-12-31 | - | - | 2025-07-14 |
| Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | NCT04335136 | Apeiron Biologics | user2@example.com | None | 2020-04-30 | 2020-12-26 | 2021-12-26 | - | - | 2025-07-14 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19 | NCT05065645 | Apeiron Biologics | user2@example.com | None | 2021-10-19 | 2022-05-27 | 2023-05-27 | - | - | 2025-07-14 |
| Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer | NCT01513278 | Apeiron Biologics | user2@example.com | None | 2012-01-31 | 2012-05-31 | 2013-05-31 | - | - | 2025-07-14 |